Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
| 대상 질환 | Human Immunodeficiency Virus, HBV, Fibrosis, Liver, Cirrhosis, Liver |
|---|---|
| 임상 단계 | 단계 해당 없음 |
| 스폰서 | University of Alabama at Birmingham |
| 상태 | 완료 |
| 참여자 수 | 349 명 |
| 중재(약물) | Anti-HIV Agents |
| 시작일 | 2015년 10월 |
| 완료일 | 2026년 5월 28일 |
| 결과 공개일 | 2026년 7월 2일 |
요약
A cohort of adults with HIV-HBV co-infection will be created in Lusaka, Zambia, to describe the short and long-term (up to 10 years of follow-up) HBV and liver outcomes, including the effectiveness of current therapies, and to identify the risk factors for major endpoints of interest, including HCC and HBV functional cure. This cohort will also create a pool of potential participants for in-depth mechanistic studies and clinical trials of novel HBV cure drugs.
Reduction in Liver Fibrosis Stage
| HBV/HIV Cohort | 46 Participants |
|---|
BENITIONS에서 보기 ClinicalTrials.gov 원문 보기
같은 질환의 다른 임상
- A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Treme — MedImmune LLC
- Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Live — National Cancer Institute (NCI)
- A Study of Nofazinlimab (CS1003) in Subjects With Advanced Hepatocellular Carcinoma — CStone Pharmaceuticals
- BMS-986205 and Nivolumab as First or Second Line Therapy in Treating Patients With Liver C — Edward Kim
- Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hep — AstraZeneca
- Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Di — National Cancer Institute (NCI)